XTL Biopharmaceuticals Regains Full Nasdaq Compliance, Resolving Multiple Delisting Threats
XTLB sits 45% above its 52-week low of $2.01.
Summary
XTL Biopharmaceuticals announced it has regained full compliance with all Nasdaq listing rules, resolving previous delisting threats related to bid price, periodic filings, and minimum stockholders' equity.
Key Events · Corporate Governance and Compliance · XTLB
-
Regained Nasdaq Compliance
The company received a letter from Nasdaq confirming it has regained compliance with Listing Rules 5101 (Public Interest), 5250(c)(1) (Periodic Filing), 5550(a)(2) (Bid Price), and 5550(b)(1) (Equity).
-
Met Bid Price Requirement
Compliance was achieved by maintaining a closing bid price above $1.00 for at least 20 consecutive trading days as of July 13, 2026.
-
Filed Annual Report
The company filed its Form 20-F for the fiscal year ended December 31, 2025, on June 30, 2026, addressing the periodic filing deficiency.
-
Achieved Minimum Equity
Following the acquisition of Psyga Bio Ltd. and a subsequent equity raise, the company now has a minimum of $2.5 million in stockholders' equity.
Analysis · XTLB · Life Sciences
XTL Biopharmaceuticals has successfully resolved multiple Nasdaq delisting issues, including bid price, periodic filing, and minimum equity requirements. This positive development removes a significant overhang and allows the company to continue its strategic pivot following the Psyga Bio acquisition. However, the company will be subject to a one-year mandatory monitoring period, meaning any future non-compliance with the Equity Rule will result in immediate delisting proceedings without further cure periods.
At the time of this filing, XTLB was trading at $2.92 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $6.3M. The 52-week trading range was $2.01 to $10.28. This filing was assessed with positive market sentiment and an importance score of 9 out of 10.